European Urology

Viewing slides 1-6 of 6

• S0302-2838(11)00477-5.title drag remove slide sort drag into slide Title New Therapies for castration-resistant prostate cancer: efficacy and safety New Therapies for castration-resistant prostate cancer: efficacy and safety Zoom
• S0302-2838(11)00477-5.introduction drag remove slide sort drag into slide Introduction Prostate cancer is the most common non-cutaneous malignancy and second leading cause of cancer mortality amongst men in the Western world.
  
  Up to 40% of men diagnosed with prostate cancer will ... Prostate cancer is the most common non-cutaneous malignancy and second leading cause of cancer ... Zoom
• 19070 drag remove slide sort drag into slide Landscape of castration-resistant prostate cancer.AR = androgen receptor. Zoom read this article »
• S0302-2838(11)00477-5.materials_and_methods drag remove slide sort drag into slide Materials and methods Electronic databases (PubMed, clinical trials.gov), relevant journals, and conference proceedings were searched manually for preclinical studies, clinical trials, and biomarker analyses focused on ... Electronic databases (PubMed, clinical trials.gov), relevant journals, and conference proceedings ... Zoom
• S0302-2838(11)00477-5.results drag remove slide sort drag into slide Results CRPC has many targets.
  
  Four new agents with different mechanisms of action have recently shown positive results in large phase 3 randomized trials.
  
  These have been approved in the United ... CRPC has many targets. Four new agents with different mechanisms of action have recently shown ... Zoom
• S0302-2838(11)00477-5.conclusion drag remove slide sort drag into slide Conclusion The landscape of how we treat patients with CRPC is changing (Figure 1).
  
  A better understanding of tumor biology, development and validation of new molecular and clinical biomarkers, and ... The landscape of how we treat patients with CRPC is changing (Figure 1). A better understanding ... Zoom

Viewing slides 1-6 of 6